MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.32
+0.12 (+0.85%)
At close: 4:00PM EDT

14.33 +0.01 (0.07%)
After hours: 7:08PM EDT

Stock chart is not supported by your current browser
Previous Close14.20
Open14.28
Bid14.33 x 800
Ask14.34 x 900
Day's Range14.00 - 14.46
52 Week Range13.03 - 29.79
Volume727,620
Avg. Volume1,274,611
Market Cap4.711B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.19
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    Moderna to Present at ROTH RNA Revolution Conference

    Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the ROTH RNA Revolution Conference on July 17, 2019.

  • Here's Why Moderna Lost 29.6% in June
    Motley Fool7 days ago

    Here's Why Moderna Lost 29.6% in June

    The post-IPO blues hit pretty hard last month.

  • Options Traders Expect Huge Moves in Moderna (MRNA) Stock
    Zacks14 days ago

    Options Traders Expect Huge Moves in Moderna (MRNA) Stock

    Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

  • Is Moderna, Inc. (MRNA) A Good Stock To Buy?
    Insider Monkey21 days ago

    Is Moderna, Inc. (MRNA) A Good Stock To Buy?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Business Wire28 days ago

    Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Moderna, Inc. (NASDAQ:MRNA): Financial Strength Analysis
    Simply Wall St.last month

    Moderna, Inc. (NASDAQ:MRNA): Financial Strength Analysis

    Stocks with market capitalization between $2B and $10B, such as Moderna, Inc. (NASDAQ:MRNA) with a size of US$5.2b, do...

  • Business Wirelast month

    Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • MIT gene-therapy spinout raises $6M, enters competitive mRNA field
    American City Business Journalslast month

    MIT gene-therapy spinout raises $6M, enters competitive mRNA field

    Strand Therapeutics hopes to create treatments using messenger RNA or mRNA, which gives instructions to the body’s cells to create proteins. But the young gene-therapy startup thinks it has created a better method than such players as Moderna Inc. and Translate Bio.

  • Business Wirelast month

    Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting

    Moderna, Inc., (MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The data showed that the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck’s pembrolizumab (KEYTRUDA®), was well-tolerated at all doses tested and elicited neoantigen-specific T-cell responses.

  • Preclinical biotech Stoke Therapeutics plans $86M IPO
    American City Business Journals2 months ago

    Preclinical biotech Stoke Therapeutics plans $86M IPO

    An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.

  • Business Wire2 months ago

    Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.

  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals2 months ago

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • Moderna, Inc. (MRNA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Moderna, Inc. (MRNA) Q1 2019 Earnings Call Transcript

    MRNA earnings call for the period ending March 31, 2019.

  • Business Wire2 months ago

    Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates

    Rare Diseases: New development candidate announced for glycogen storage disease type 1a , a rare metabolic disorder; Company now has five rare disease programs in its pipeli

  • Why Earnings Season Could Be Great for Moderna (MRNA)
    Zacks2 months ago

    Why Earnings Season Could Be Great for Moderna (MRNA)

    Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Business Wire2 months ago

    Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire3 months ago

    Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    The Company and academic collaborators to share data from seven preclinical studies demonstrating the potential of mRNA-based therapies to treat rare metabolic and genetic disorder

  • 7 Strong Buy Stocks the Street Loves
    InvestorPlace3 months ago

    7 Strong Buy Stocks the Street Loves

    [Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with no "hold" or "sell" ratings and a pure "strong buy" analyst consensus. These are the strong buy stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the unanimous support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "strong buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * 5 Dividend Stocks Perfect for Retirees Now let's delve into these seven top stocks to buy now:Source: Shutterstock Strong Buy Stocks: Exact Sciences (EXAS)Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate. As it prepares to release its Q1 numbers April 30, those numbers still look achievable.Plus the future looks bright for sales for its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $104. Bear in mind shares have surged 45% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report.Source: Shutterstock OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * 10 S&P 500 Stocks to Weather the Earnings Storm That level of optimism still is on Open Text's side as it prepares its May 1 report report on third-quarter earnings."We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Overall, five analysts have published recent bullish calls on the stock. That's with a $46.75 average price target -- 23% upside potential from the current share price. Shares are up 17% year-to-date. Get the OTEX Stock Research Report.Source: Shutterstock Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Right now the company just reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024.With a $27 price target, Cann sees upside potential of 19% for the coming months. Shares are currently surging more than 45% in 2019. Get the MRNA Stock Research Report.Source: Flash.pro via Flickr (modified) Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received six recent buy calls from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December. As a result, Nextar Media stock now scores unanimous support.Crucially, the company is on the verge of a fresh acquisition. It has agreed a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112 (23% upside potential) adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report.Source: Ace Via on Flickr Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have exploded by 11% in just five days. That's thanks to a pretty exceptional earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "As we get late into EPS season, we believe we have seen the best print to date, with BYD's strong 4Q18 results tonight, an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a "strong buy" analyst consensus, BYD boasts five recent buy ratings and a $37.80 average price target (22% upside potential). Get the BYD Stock Research Report.Source: Shutterstock LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company has just hit all-time highs following its strongest revenue growth in three years. For the third time in a row, LPSN reported 14% quarterly revenue growth. Shares are now up 50% year-to-date.Even if the company can't keep up the pace when it reports earnings May 2, it still is a keeper.Going forward, analysts are firmly bullish about LivePerson's outlook. Seven analysts have published recent buy ratings on the stock, including (five-star Oppenheimer analyst Koji Ikeda. * 7 AI Stocks to Watch with Strong Long-Term Narratives "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report.Source: Shutterstock Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, Growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's most recent earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams writes: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.80. Get the CUB Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio Compare Brokers The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.

  • Business Wire3 months ago

    Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update. Moderna’s Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Moderna’s mRNA Research Platform with a focus on the Company’s newest advances from its commitment to basic and applied sciences.

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks3 months ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
    Motley Fool3 months ago

    3 Biotech Stocks That Doubled After Hitting Bottom in 2018

    Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.

  • CNBC3 months ago

    Cramer's lightning round: I promised my kids I wouldn't, but I recommend this stock

    Jim Cramer zips through his thoughts on callers' questions about their stock picks of the day.